Increased Overall Survival for Subcutaneous Versus Intravenous Daratumumab in Medicare Beneficiaries With Multiple Myeloma
Clinical Lymphoma Myeloma and Leukemia · 2026-11
DOI: 10.1016/j.clml.2026.08.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-11. Verfasst von Daniel Gomes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Voxanalytica LLC/Institute4HSR, Pleasanton, CA. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Halozyme Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Voxanalytica LLC/Institute4HSR, Pleasanton, CA.
- Halozyme Therapeutics, Inc., San Diego, CA.
- Halozyme Therapeutics, Inc., San Diego, CA. Electronic address: publications@halozyme.com.
- Department of Medicine, NYU Grossman School of Medicine, New York, NY.
- Independent Patient Research Advocate, Coto de Caza, CA.
- Memorial Sloan Kettering Cancer Center, New York, NY.
Förderung
- Halozyme Inc
Zitieren
APA
Gomes, D., Sarocco, P., Theuer, C. P., Morgan, G., Kennedy, T., Santos Estrella, P., Zhou, J., & Usmani, S. Z. (2026). Increased Overall Survival for Subcutaneous Versus Intravenous Daratumumab in Medicare Beneficiaries With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.08.016
Vancouver
Gomes D, Sarocco P, Theuer CP, Morgan G, Kennedy T, Santos Estrella P, et al. Increased Overall Survival for Subcutaneous Versus Intravenous Daratumumab in Medicare Beneficiaries With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.08.016
BibTeX
@article{Gomes2026,
author = {Gomes, Daniel and Sarocco, Phillip and Theuer, Charles P and Morgan, Gareth and Kennedy, Todd and Santos Estrella, Paul and Zhou, Jimmy and Usmani, Saad Z},
title = {Increased Overall Survival for Subcutaneous Versus Intravenous Daratumumab in Medicare Beneficiaries With Multiple Myeloma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2026.08.016}
}
EUVIMED